Overview

Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This phase II single arm, open-label study investigate the safety of a second cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after treatment in the CASIMAS study.
Phase:
Phase 2
Details
Lead Sponsor:
Neovii Biotech
Treatments:
Antibodies, Bispecific
Catumaxomab